Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Macrophage immune checkpoint inhibitors like anti-CD47 antibodies are promising for cancer treatment.
• Optimal combination strategies for these therapies are not yet established.
• Synergistic effects are anticipated when combined with other anticancer agents.

Purpose of the Study:

• To identify drugs enhancing lung cancer cell vulnerability to macrophage attack.
• To investigate the therapeutic synergy between genotype-directed therapies and anti-CD47 antibodies.
• To explore underlying molecular mechanisms of enhanced anti-cancer activity.

Main Methods:

• Development of an unbiased, high-throughput drug screening platform.
• In vitro phagocytosis assays and persister cell elimination studies.
• In vivo antitumor response assessments in preclinical models.
• Analysis of molecular mechanisms including β2-microglobulin and CD73 expression.

Main Results:

• Therapeutic synergy was identified between genotype-directed therapies and anti-CD47 antibodies.
• The combination therapy induced robust phagocytosis and eliminated persister cells in vitro.
• Maximized antitumor responses were observed in vivo.
• Findings were applicable across various RTK/MAPK pathway alterations (EGFR, ALK, KRASG12C).
• Downregulation of β2-microglobulin and CD73 contributed to enhanced macrophage attack sensitivity.

Conclusions:

• Dual inhibition of the RTK/MAPK pathway and the CD47/SIRPa axis represents a promising immunotherapeutic strategy.
• This combination therapy demonstrates significant potential for lung cancers with driver mutations.
• Further clinical investigation of this combination in lung cancer patients is warranted.